Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0233)
| Name |
Carnosic acid
|
||||
|---|---|---|---|---|---|
| Synonyms |
Carnosic acid; 3650-09-7; Salvin; Carnosicacid; LI791SXT24; CHEBI:65585; 139236-75-2; UNII-LI791SXT24; 11,12-dihydroxyabieta-8,11,13-trien-20-oic acid; NSC694080; (4aR,10aS)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-4a-carboxylic Acid; 11,12-dihydroxy-13-isopropylpodocarpa-8,11,13-trien-17-oic acid; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2H)-carboxylic acid; 4a(2H)-Phenanthrenecarboxylic acid, 1,3,4,9,10,10a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1-methylethyl)-, (4aR,10aS)-rel-; 4a(2H)-Phenanthrenecarboxylic acid, 1,3,4,9,10,10a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1-methylethyl)-, (4aR-trans)-; RoseOx; CARNOSIC ACID (USP-RS); CARNOSIC ACID [USP-RS]; Podocarpa-8,11,13-trien-17-oic acid, 11,12-dihydroxy-13-isopropyl-; (4AR,10AS)-1,3,4,9,10,10A-HEXAHYDRO-5,6-DIHYDROXY-1,1-DIMETHYL-7-(1-METHYLETHYL)-4A(2H)-PHENANTHRENECARBOXYLIC ACID; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid; Rosamox; Carnosic-acid; Carsonic acid; Carnosic acid; MFCD02259459; Deoxypicrosalvinic acid; UPCMLD-DP056; CARNOSIC ACID [MI]; CARNOSIC ACID [INCI]; CHEMBL484853; SCHEMBL9923661; UPCMLD-DP056:001; DTXSID20904450; QRYRORQUOLYVBU-VBKZILBWSA-N; BCPP000299; Carnosic acid, analytical standard; HY-N0644; BDBM50371232; s3838; AKOS015901362; AC-6030; BCP9000491; CCG-207954; NSC-694080; SMP2_000204; NCGC00161623-01; AS-31052; NCI60_033653; BCP0726000155; C2488; C3477; CS-0009671; C21818; CARNOSIC ACID (CONSTITUENT OF ROSEMARY); A918580; Q412827; SR-05000002202; SR-05000002202-2; CARNOSIC ACID (CONSTITUENT OF ROSEMARY) [DSC]; Carnosic acid, primary pharmaceutical reference standard; Carnosic acid from Rosmarinus officinalis, >=91%, powder; Carnosic acid, United States Pharmacopeia (USP) Reference Standard; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylicacid
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C20H28O4
|
||||
| IUPAC Name |
(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid
|
||||
| Canonical SMILES |
CC(C)C1=C(C(=C2C(=C1)CCC3C2(CCCC3(C)C)C(=O)O)O)O
|
||||
| InChI |
InChI=1S/C20H28O4/c1-11(2)13-10-12-6-7-14-19(3,4)8-5-9-20(14,18(23)24)15(12)17(22)16(13)21/h10-11,14,21-22H,5-9H2,1-4H3,(H,23,24)/t14-,20+/m0/s1
|
||||
| InChIKey |
QRYRORQUOLYVBU-VBKZILBWSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 2 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Marker/Suppressor | |||
| Responsed Disease | Oral squamous cell carcinoma | ICD-11: 2B6E | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Cell Process | Cell ferroptosis | |||
| Response regulation | The current findings highlight that carnosic acid may re-sensitize cisplatin-resistant cells to cisplatin by inducing ferroptosis, which involves the inactivation of Nrf2/HO-1/xCT pathway. Hence, this research may support a promising therapeutic approach to overcome chemoresistance in Oral squamous cell carcinoma. | |||
| Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target | [2] | |||
| Target for Ferroptosis | Marker/Suppressor | |||
| Responsed Disease | Spinal cord injury | ICD-11: ND51 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | PC12 cells | Adrenal gland pheochromocytoma | Rattus norvegicus | CVCL_0481 |
| Response regulation | Ferroptosis is involved in the pathogenesis of spinal cord injury (SCI). Carnosic acid (CA) is a natural phenolic diterpene, which possesses diversiform activities. CA can inhibit ferroptosis in PC12 cells induced by erastin via activating Nrf2 pathway, indicating that CA could lead to neuroprotective effect by restraining the occurrence of ferroptosis. | |||
Heme oxygenase 1 (HMOX1)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Oral squamous cell carcinoma | ICD-11: 2B6E | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Cell Process | Cell ferroptosis | |||
| Response regulation | The current findings highlight that carnosic acid may re-sensitize cisplatin-resistant cells to cisplatin by inducing ferroptosis, which involves the inactivation of Nrf2/HO-1/xCT pathway. Hence, this research may support a promising therapeutic approach to overcome chemoresistance in Oral squamous cell carcinoma. | |||
References